Acceleron Pharma Inc. (XLRN) Rose to $48.60

June 29, 2018 - By Gwen Gough

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

Big Money Sentiment increased to 1.27 in Q1 2018. It has change of 0.18, from 2017Q4’s 1.09. The ratio is positive due to Acceleron Pharma Inc. positioning: 13 sold and 39 reduced. 24 funds bought stakes and 42 increased stakes. Investors holded 38.14 million in 2017Q4 but now own 38.30 million shares or 0.44% more.
Riverhead accumulated 166 shs or 0% of the stock. Great Point Ltd Company has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Savings Bank Of America Corp De holds 57,195 shs or 0% of its capital. Granahan Investment Inc Ma reported 232,746 shs stake. Moreover, Invesco Limited has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 5,611 shs. Public Employees Retirement Association Of Colorado owns 3,246 shs or 0% of their US capital. Eagle Asset Mngmt stated it has 1.23M shs. C Gru A S has 4,537 shs for 0% of their capital. New York-based Bluemountain Capital Limited Liability has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Bamco New York holds 0.01% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 56,815 shs. Trexquant Invest L P owns 0.02% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 8,292 shs. Goldman Sachs accumulated 555,019 shs. 163,900 were reported by Baker Bros Advsr Limited Partnership. Dupont Capital Management invested in 0% or 4,811 shs. Bnp Paribas Arbitrage Sa reported 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN).

Acceleron Pharma Inc. had 12 insider sales and 0 insider buys since January 2, 2018. This’s net activity of $4.08 million. Rovaldi Christopher sold $495,000 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 11,000 shs on Friday, January 12. Quisel John D had sold 1,204 shs worth $46,232 on Tuesday, April 3. Kumar Ravindra had sold 1,203 shs worth $46,205. The insider MCLAUGHLIN KEVIN F sold 4,000 shs worth $153,792. POPS RICHARD F had sold 37,500 shs worth $1.55 million.

Acceleron Pharma Inc. (NASDAQ:XLRN) increased significantly to $48.60. On Jun, 29 the move was announced by It has $2.23 billion MC. The company’s valuation will be $66.75M more at $50.06 target.

Acceleron Pharma Inc. (NASDAQ:XLRN) is expected to announce earnings on August, 2., RTT reports. EPS of $-0.64 is 16.88 % up from 2017’s $-0.77 EPS. After $-0.58 EPS was announced last quarter, analysts now see negative EPS growth of 10.34 % for Acceleron Pharma Inc..

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Total analysts of 7 have positions in Acceleron Pharma (NASDAQ:XLRN) as follows: 5 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 71%. Since January 8, 2018 according to StockzIntelligence Inc Acceleron Pharma has 9 analyst reports. On Thursday, March 1 the firm has “Buy” rating by Citigroup given. The company rating was upgraded by JP Morgan on Monday, February 26. On Friday, June 29 Goldman Sachs upgraded Acceleron Pharma Inc. (NASDAQ:XLRN) rating. Goldman Sachs has “Neutral” rating and $40 target. On Tuesday, May 22 the stock has “Hold” rating by Oppenheimer. In Monday, January 8 report H.C. Wainwright initiated it with “Buy” rating and $62.0 target. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, February 28. On Friday, June 29 Credit Suisse maintained Acceleron Pharma Inc. (NASDAQ:XLRN) with “Outperform” rating. In Wednesday, March 28 report H.C. Wainwright initiated the stock with “Buy” rating. On Wednesday, February 28 the rating was maintained by Barclays Capital with “Overweight”.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news released briefly go to:,,, or The titles are as follows: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” released on June 29, 2018, “Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn’t Buying” on June 29, 2018, “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” with a publish date: June 29, 2018, “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” and the last “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” with publication date: June 22, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The company has $2.23 billion market cap. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Currently it has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: